 CAMBRIDGE, Mass., April 09, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in UPLIFT, a single-arm registration strategy to evaluate the safety and efficacy of upifitamab rilsodotin UpRi, XMT-1536 in patients with platinum-resistant ovarian cancer who have received up to four lines of therapy. 